Printer Friendly

CEPHALON APPOINTS VICE PRESIDENT, WORLDWIDE CLINICAL RESEARCH

 WEST CHESTER, Pa., Oct. 26 /PRNewswire/ -- Cephalon, Inc. (NASDAQ: CEPH) announced today the appointment of Michael F. Murphy, M.D., Ph.D. as Vice President, Worldwide Clinical Research, a new position. Dr. Murphy will be responsible for managing all of the company's clinical development programs.
 Dr. Murphy, age 47, was vice president, Scientific and Professional Affairs, Neuroscience-Strategic Business Unit at Hoechst-Roussel Pharmaceuticals, Inc. During his 10 years with Hoechst he held various clinical development positions where he was responsible for worldwide clinical development of the company's central nervous system therapeutics, including compounds for depression, Alzheimer's disease, vascular dementia and schizophrenia. Dr. Murphy currently serves as a Clinical Assistant Professor of Psychiatry at the University of Medicine and Dentistry New Jersey-Rutgers and Mount Sinai School of Medicine in New York. He received his medical degree and doctorate in Pharmacology from Tulane University, and board certification in Psychiatry after training at Stanford University and Mount Sinai School of Medicine.
 "We are fortunate to have found in Michael Murphy a person with extensive experience and an in-depth understanding of issues relevant to the drug discovery and clinical development process within neuroscience. The creation of this position will allow each of our medical directors to focus on individual programs while allowing Dr. Murphy to manage from a global perspective," said Frank Baldino Jr., Ph.D., president and CEO of Cephalon. "The success of our discovery programs has resulted in a tremendous expansion of our clinical research activities. Dr. Murphy's insight and skills in managing such a broad-based clinical program will be a great benefit to the company."
 Cephalon is currently conducting Phase II/III clinical trials of Myotrophin(TM) for the treatment of amyotrophic lateral sclerosis in the United States and Europe and U.S. clinical trials of modafinil for the treatment of narcolepsy. The company also plans to initiate clinical testing of Myotrophin for the treatment of chemotherapy-induced neuropathy in the next several months.
 Cephalon, Inc. is a leader in the discovery and development of products to treat neurological diseases and disorders. The company's principal focus is on neurodegenerative diseases such as ALS, peripheral neuropathy, Alzheimer's disease, head and spinal cord injury, and stroke.
 /delval/
 -0- 10/26/93
 /CONTACT: Jason Rubin or Lyn Hyduke, corporate communications, of Cephalon, 215-344-0200, or Karen Bergman of Burns McClellan, 212-505-1919, for Cephalon/
 (CEPH)


CO: Cephalon, Inc. ST: Pennsylvania IN: MTC SU: PER

MJ-MS -- PH002 -- 6712 10/26/93 08:29 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 26, 1993
Words:405
Previous Article:JONES APPAREL GROUP, INC. REPORTS RECORD THIRD QUARTER SALES AND EARNINGS
Next Article:PRIMADONNA RESORTS INC. REPORTS RECORD THIRD QUARTER EARNINGS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters